MedTrace Logo

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

NCT06783127 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-02-11

No results posted yet for this study

Summary

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Conditions

Interventions

DRUG

Olaparib

Olaparib given according the clinical practice to BRCA positive mCRPC patients

Sponsors & Collaborators

  • Santa Chiara Hospital

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783127 on ClinicalTrials.gov